eligibility_summary
Eligible: CTCL (e.g., MF, SS, pcALCL) with relapse after prior response (CR/PR/SD) to brentuximab vedotin (BV), previously received BV in ≥2 lines of therapy (other treatments allowed between), and has completed ≥3 cycles of BV retreatment. Exclusions: none.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial type: observational, retrospective real‑world study of adults with CTCL retreated with brentuximab vedotin (BV), no study-administered therapy (chart review only). Drug/intervention: brentuximab vedotin (ADC, anti‑CD30 IgG1 monoclonal antibody linked to the cytotoxic payload monomethyl auristatin E [MMAE], a microtubule inhibitor). Mechanism of action: BV binds CD30 on tumor cells, is internalized, linker is proteolytically cleaved in lysosomes to release MMAE, which disrupts tubulin polymerization, causing G2/M arrest and apoptosis, potential ADCC and bystander cytotoxicity may contribute. Cells/pathways targeted: CD30‑expressing malignant cutaneous T lymphocytes in CTCL (e.g., mycosis fungoides, Sézary syndrome, primary cutaneous CD30+ ALCL), targets CD30 receptor and the microtubule/cell‑cycle machinery.